Your Health, We Care
Release date: 2026-01-21 17:07:50 Recommended: 21
Ponatinib is a targeted therapy indicated for the treatment of specific types of leukemia, such as chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its common adverse reactions include vascular occlusive events, hypertension, skin rashes, and headaches. Severe side effects may involve pancreatitis, cardiac arrhythmias, and increased bleeding risk. The medication must be administered strictly in accordance with medical advice.
Vascular occlusive events: Arterial or venous thrombosis (e.g., myocardial infarction, stroke, deep vein thrombosis) represents one of the most serious risks associated with ponatinib.
Hypertension: Elevated blood pressure may occur in approximately 30%–50% of patients, requiring close monitoring.
Cutaneous reactions: Rashes, dry skin, pruritus and other symptoms may appear, some of which may progress to severe dermatitis.
Other reactions: Headache, arthralgia, fatigue, constipation or diarrhea.
Pancreatitis: Manifested as abdominal pain, nausea and vomiting, which requires monitoring via blood tests (e.g., amylase and lipase levels).
Cardiac arrhythmias: Including QT interval prolongation, tachycardia or atrial fibrillation, which may lead to syncope or heart failure.
Increased bleeding risk: Gastrointestinal bleeding, intracranial hemorrhage and other conditions may occur, with the risk heightened especially when combined with anticoagulant drugs.
Hepatic injury: Elevated transaminase or bilirubin levels may present, necessitating regular liver function tests.
Myelosuppression: Neutropenia or thrombocytopenia may develop, potentially increasing the risk of infection or bleeding.
Metabolic abnormalities: Hyperglycemia, hypocalcemia and other disorders may occur, requiring regular monitoring of electrolytes and blood glucose levels.
Gastrointestinal reactions: Abdominal pain, nausea and vomiting may affect nutritional intake, which requires symptomatic management.
Cardiotoxicity: Long-term use may induce heart failure or cardiomyopathy.
Strict adherence to medical advice: Dosage should be adjusted based on disease status and side effects. Patients must not discontinue the medication or modify the treatment regimen without authorization.
Regular monitoring: During treatment, regular monitoring of blood pressure, electrocardiogram (ECG), complete blood count (CBC), liver and renal function, as well as coagulation function is required.
Symptom alert: Immediate medical attention is needed if symptoms such as chest pain, dyspnea, limb swelling, severe headache or visual changes occur.
Note: Ponatinib is a prescription-only medication. It must be used under the guidance of hematology or oncology specialists, with a comprehensive assessment of cardiovascular risks versus treatment benefits.
